Research based on cancer cells in the blood, such as Circulating Tumour Cells (CTCs) and ctDNA has generated much interest, opening the potential to a `Liquid Biopsy' option, as an alternative to a conventional tissue biopsy; thus allowing a better routine monitoring system, and robust genetic characterisation of the cancer. The concept of tumour and cancer profiling from blood components is an exciting field, opening the potential to solve many issues currently surrounding cancer diagnosis/prognosis and treatment. At CBCEL we have teamed up with numerous hospitals to study the clinical benefits of liquid biopsies.
Circulating Tumour Cells
Circulating tumour cells are cells that shed from the primary tumour and are found in peripheral blood with all major carcinomas. CTCs, as liquid biopsies, hold a tremendous potential for providing new biological insights and is being studied intensively for its significance as a prognostic, diagnostic and predictive biomarker, especially for early detection of malignancy. At CBCEL we are using cutting-edge imaging flow-cytometry techniques to characterice and enumerate CTCs from various cancers, including ovarian, lung, rectal, prostate and anal.
Endocrine Disrupting Chemicals
Endocrine Disrupting Chemicals (EDCs) are mostly man-made chemicals that are found in various materials such as pesticides, plastics, industrial chemicals, and personal care products. EDCs have been associated with obesity, diabetes, breast cancer, and altered reproductive function in males and females. At CBCEL we are studying the effects of EDCs on the human placenta.